Cassava Sciences, Inc., a clinical-stage biotechnology company, announced on February 7, 2024, the top-line results of a two-year clinical safety study of simufilam, its investigational oral drug for Alzheimer's disease dementia. The study, which enrolled over 200 patients with mild to moderate Alzheimer's, showed that patients with mild Alzheimer's who received continuous simufilam treatment for 24 months had stable ADAS-Cog scores, indicating no decline in cognition. In contrast, those who received non-continuous treatment declined by an average of 1 point on the ADAS-Cog scale. The study also reported that simufilam was safe and well-tolerated, with no drug-related serious adverse events. Cassava Sciences plans to present the detailed data from this study in a scientific...Show More

Cassava Sciences, Inc., a clinical-stage biotechnology company, announced on February 7, 2024, the top-line results of a two-year clinical safety study of simufilam, its investigational oral drug for Alzheimer's disease dementia. The study, which enrolled over 200 patients with mild to moderate Alzheimer's, showed that patients with mild Alzheimer's who received continuous simufilam treatment for 24 months had stable ADAS-Cog scores, indicating no decline in cognition. In contrast, those who received non-continuous treatment declined by an average of 1 point on the ADAS-Cog scale. The study also reported that simufilam was safe and well-tolerated, with no drug-related serious adverse events. Cassava Sciences plans to present the detailed data from this study in a scientific forum. Additionally, the company is conducting two fully enrolled global Phase 3 clinical studies of simufilam, with top-line results expected by the end of 2024 and mid-year 2025, respectively. The announcement emphasized that the open-label study's results do not constitute regulatory evidence of safety or efficacy, and rigorous evidence would come from randomized, placebo-controlled studies.